Cetera Investment Advisers Raises Position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Cetera Investment Advisers raised its holdings in shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 2.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 27,893 shares of the company’s stock after buying an additional 561 shares during the quarter. Cetera Investment Advisers’ holdings in Invesco Biotechnology & Genome ETF were worth $1,808,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the business. Covestor Ltd increased its stake in Invesco Biotechnology & Genome ETF by 24.2% in the first quarter. Covestor Ltd now owns 955 shares of the company’s stock valued at $62,000 after acquiring an additional 186 shares during the last quarter. Commonwealth Equity Services LLC increased its position in shares of Invesco Biotechnology & Genome ETF by 1.9% during the 1st quarter. Commonwealth Equity Services LLC now owns 13,862 shares of the company’s stock valued at $897,000 after purchasing an additional 256 shares during the last quarter. US Bancorp DE raised its holdings in shares of Invesco Biotechnology & Genome ETF by 1.8% during the 1st quarter. US Bancorp DE now owns 16,800 shares of the company’s stock valued at $1,087,000 after buying an additional 300 shares in the last quarter. Ashton Thomas Private Wealth LLC bought a new stake in Invesco Biotechnology & Genome ETF in the 2nd quarter worth approximately $26,000. Finally, Investment House LLC boosted its stake in Invesco Biotechnology & Genome ETF by 6.3% in the second quarter. Investment House LLC now owns 7,635 shares of the company’s stock worth $495,000 after buying an additional 450 shares in the last quarter.

Invesco Biotechnology & Genome ETF Price Performance

Shares of NYSEARCA PBE opened at $69.96 on Tuesday. The stock has a market capitalization of $282.66 million, a P/E ratio of 17.12 and a beta of 0.88. Invesco Biotechnology & Genome ETF has a one year low of $52.47 and a one year high of $72.72. The firm’s 50 day simple moving average is $69.84 and its two-hundred day simple moving average is $66.46.

Invesco Biotechnology & Genome ETF Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.